NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.220
-0.040 (-1.77%)
At close: Apr 10, 2026, 4:00 PM EDT
2.234
+0.014 (0.65%)
After-hours: Apr 10, 2026, 7:31 PM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover NRx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $34, which forecasts a 1,431.53% increase in the stock price over the next year. The lowest target is $18 and the highest is $48.
Price Target: $34 (+1,431.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,431.53% | Mar 24, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +1,026.13% | Mar 24, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,431.53% | Mar 17, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,431.53% | Mar 16, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,431.53% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
32.44M
from 1.23M
Increased by 2,547.84%
Revenue Next Year
548.73M
from 32.44M
Increased by 1,591.73%
EPS This Year
0.31
from -1.34
EPS Next Year
1.19
from 0.31
Increased by 290.00%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 33.4M | 582.3M | |||
| Avg | 32.4M | 548.7M | |||
| Low | 31.2M | 511.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2,625.7% | 1,695.1% | |||
| Avg | 2,547.8% | 1,591.7% | |||
| Low | 2,444.0% | 1,475.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.32 | 1.23 | |
| Avg | 0.31 | 1.19 | |
| Low | 0.29 | 1.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 301.5% | |
| Avg | - | 290.0% | |
| Low | - | 274.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.